113 related articles for article (PubMed ID: 1600608)
1. Relationship between the debrisoquine hydroxylase polymorphism and cancer susceptibility.
Wolf CR; Smith CA; Gough AC; Moss JE; Vallis KA; Howard G; Carey FJ; Mills K; McNee W; Carmichael J
Carcinogenesis; 1992 Jun; 13(6):1035-8. PubMed ID: 1600608
[TBL] [Abstract][Full Text] [Related]
2. Molecular genetic analysis of the cytochrome P450-debrisoquine hydroxylase locus and association with cancer susceptibility.
Smith CA; Moss JE; Gough AC; Spurr NK; Wolf CR
Environ Health Perspect; 1992 Nov; 98():107-12. PubMed ID: 1486838
[TBL] [Abstract][Full Text] [Related]
3. Debrisoquine hydroxylase gene polymorphism in meningioma.
Wundrack I; Meese E; Müllenbach R; Blin N
Acta Neuropathol; 1994; 88(5):472-4. PubMed ID: 7847077
[TBL] [Abstract][Full Text] [Related]
4. Correlation of polymorphic expression of CYP2D6 mRNA in bladder mucosa and tumor tissue to in vivo debrisoquine hydroxylase activity.
Romkes-Sparks M; Mnuskin A; Chern HD; Persad R; Fleming C; Sibley GN; Smith P; Wilkinson GR; Branch RA
Carcinogenesis; 1994 Sep; 15(9):1955-61. PubMed ID: 7923590
[TBL] [Abstract][Full Text] [Related]
5. PCR-based CYP2D6 genotyping for Finnish lung cancer patients.
Hirvonen A; Husgafvel-Pursiainen K; Anttila S; Karjalainen A; Pelkonen O; Vainio H
Pharmacogenetics; 1993 Feb; 3(1):19-27. PubMed ID: 8097947
[TBL] [Abstract][Full Text] [Related]
6. Identification of the primary gene defect at the cytochrome P450 CYP2D locus.
Gough AC; Miles JS; Spurr NK; Moss JE; Gaedigk A; Eichelbaum M; Wolf CR
Nature; 1990 Oct; 347(6295):773-6. PubMed ID: 1978251
[TBL] [Abstract][Full Text] [Related]
7. Debrisoquine hydroxylase gene polymorphism and susceptibility to Parkinson's disease.
Smith CA; Gough AC; Leigh PN; Summers BA; Harding AE; Maraganore DM; Sturman SG; Schapira AH; Williams AC
Lancet; 1992 Jun; 339(8806):1375-7. PubMed ID: 1350805
[TBL] [Abstract][Full Text] [Related]
8. CYP2D6-debrisoquine hydroxylase gene polymorphism in multiple system atrophy.
Planté-Bordeneuve V; Bandmann O; Wenning G; Quinn NP; Daniel SE; Harding AE
Mov Disord; 1995 May; 10(3):277-8. PubMed ID: 7651442
[TBL] [Abstract][Full Text] [Related]
9. Mutant genes of cytochrome P-450IID6, glutathione S-transferase class Mu, and arylamine N-acetyltransferase in lung cancer patients.
Roots I; Brockmöller J; Drakoulis N; Loddenkemper R
Clin Investig; 1992; 70(3-4):307-19. PubMed ID: 1355678
[TBL] [Abstract][Full Text] [Related]
10. Human debrisoquine hydroxylase gene polymorphisms in cancer patients and controls.
Sugimura H; Caporaso NE; Shaw GL; Modali RV; Gonzalez FJ; Hoover RN; Resau JH; Trump BF; Weston A; Harris CC
Carcinogenesis; 1990 Sep; 11(9):1527-30. PubMed ID: 1976046
[TBL] [Abstract][Full Text] [Related]
11. Metabolic cytochrome P450 genotypes and assessment of individual susceptibility to lung cancer.
Hirvonen A; Husgafvel-Pursiainen K; Anttila S; Karjalainen A; Sorsa M; Vainio H
Pharmacogenetics; 1992 Dec; 2(6):259-63. PubMed ID: 1306126
[TBL] [Abstract][Full Text] [Related]
12. Human CYP2D6 gene polymorphism in Slovene cancer patients and healthy controls.
Dolzan V; Rudolf Z; Breskvar K
Carcinogenesis; 1995 Nov; 16(11):2675-8. PubMed ID: 7586185
[TBL] [Abstract][Full Text] [Related]
13. Individuality in cytochrome P450 expression and its association with the nephrotoxic and carcinogenic effects of chemicals.
Wolf CR
IARC Sci Publ; 1991; (115):281-7. PubMed ID: 1820342
[TBL] [Abstract][Full Text] [Related]
14. Concordance of P450 2D6 (debrisoquine hydroxylase) phenotype and genotype: inability of dextromethorphan metabolic ratio to discriminate reliably heterozygous and homozygous extensive metabolizers.
Evans WE; Relling MV
Pharmacogenetics; 1991 Dec; 1(3):143-8. PubMed ID: 1688245
[TBL] [Abstract][Full Text] [Related]
15. Debrisoquine hydroxylase gene polymorphism frequencies in patients with amyotrophic lateral sclerosis.
Siddons MA; Pickering-Brown SM; Mann DM; Owen F; Cooper PN
Neurosci Lett; 1996 Apr; 208(1):65-8. PubMed ID: 8731176
[TBL] [Abstract][Full Text] [Related]
16. Detection of DNA sequence polymorphisms in carcinogen metabolism genes by polymerase chain reaction.
Bell DA
Environ Mol Mutagen; 1991; 18(4):245-8. PubMed ID: 1684153
[TBL] [Abstract][Full Text] [Related]
17. Debrisoquine hydroxylation phenotype, acetylation phenotype, and ABO blood groups as genetic host factors of lung cancer risk.
Roots I; Drakoulis N; Ploch M; Heinemeyer G; Loddenkemper R; Minks T; Nitz M; Otte F; Koch M
Klin Wochenschr; 1988; 66 Suppl 11():87-97. PubMed ID: 2846954
[TBL] [Abstract][Full Text] [Related]
18. DNA haplotype dependency of debrisoquine 4-hydroxylase (CYP2D6) expression among extensive metabolisers.
Mura C; Panserat S; Vincent-Viry M; Galteau MM; Jacqz-Aigrain E; Krishnamoorthy R
Hum Genet; 1993 Oct; 92(4):367-72. PubMed ID: 7901140
[TBL] [Abstract][Full Text] [Related]
19. Dinucleotide repeat polymorphism at the debrisoquine 4-hydroxylase (CYP2D) locus.
Trofatter JA; Gusella JF; Haines JL
Nucleic Acids Res; 1991 May; 19(10):2802. PubMed ID: 2041763
[No Abstract] [Full Text] [Related]
20. Dinucleotide repeat polymorphism at the human debrisoquine 4-hydroxylase (CYP2D) locus.
Polymeropoulos MH; Rath DS; Xiao H; Merril CR
Nucleic Acids Res; 1991 Apr; 19(8):1961. PubMed ID: 2030982
[No Abstract] [Full Text] [Related]
[Next] [New Search]